Tuberculosis, or TB, is the leading infectious killer globally; in 2017 there were 10 million cases of the disease and 1.6 million deaths. Recent years have seen huge progress in research but more action is still needed, so where did the story start?
The latest report from the ECDC and WHO has analysed the 2017 data for the European region, suggesting that despite an overall decline in the number of cases, TB remains a major public health challenge.
Dr. Suvanand Sahu, Deputy Executive Director, at the Stop TB Partnership, reflects on the UNHLM on TB outlining the progress that was made and what more needs to be done.
In line with World Tuberculosis Day 2019, we are hosting a Twitter chat #TalkTB with prominent experts in the field of tuberculosis on Thursday March 21 at 11:00 EDT / 15:00 GMT.
Find out more about the headlines from the Conference on Retroviruses and Opportunistic Infections 2019 (CROI) in our round-up of conference news.
Researchers have investigated a toxin–antitoxin system in tuberculosis as a therapeutic target, providing the first high-resolution details.
New data analysis of three clinical trials has suggested that a precision medicine approach could allow some pulmonary TB patients to have significantly shorter treatment periods.
On the day of UNGA’s first-ever high-level meeting on tuberculosis we summarize the key points from the WHO 2018 Global Tuberculosis Report and what this meeting could mean for accelerating progress.
A study using standardized patients has reported that private practitioners in India are delivering a wide range of often inadequate care to tuberculosis patients.
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…
